

Haematologica
HAEMATOL/2018/210971
Version 3

Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial

Francis Couturaud, Gilles Pernod, Emilie Presles, Elisabeth Duhamel, Patrick Jego, Karine Provost, Brigitte Pan-Petes, Claire Bal dit Sollier, Cécile Tromeur, Clément Hoffman, Luc Bressollette, Philippe Lorillon, Philippe Girard, Emmanuelle Le Moigne, Aurélia Le Hir, Marie Guégan, Silvy Laporte, Patrick Mismetti, Karine Lacut, Jean-Luc Bosson, Laurent Bertoletti, Olivier Sanchez, Guy Meyer, Christophe Leroyer, and Dominique Mottier

Disclosures: Funding/Support: The study was supported by grants from the "Programme Hospitalier de Recherche Clinique" (French Department of Health), the "Fondation de France", and the sponsor was the University Hospital of Brest. The University hospital of Brest, the study sponsor, had no role in the design or conduct of the trial, data analysis, or preparation of the manuscript. Role of the funding source: The funding source was not involved in designing or conducting the study, collecting, managing, analyzing or interpreting the data, preparing, reviewing or approving the manuscript, or deciding to submit this for publication. An academic steering committee assumed overall responsibility for all these steps. Dr Couturaud takes responsibility for data access and integrity of the data. Conflict of interest disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Couturaud reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer and Astra Zeneca and having received travel support from Bayer, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Leo Pharma, Intermune and Actelion. Dr. Pernod declares he has no conflict of interest related to this research. Ms. Presles declares she has no conflict of interest related to this research. Dr. Duhamel declares she has no conflict of interest related to this research. Dr. Jego reports having received personal fees or non-financial support from Sanofi, GlaxoSmithKline, Bayer, Boehringer Ingelheim, and Leo Pharma. Dr. Provost declares she has no conflict of interest related to this research. Dr. Provost declares she has no conflict of interest related to this research. Ms. Bal dit Sollier declares she has no conflict of interest related to this research. Dr Clément Hoffmann declares he has no conflict of interest related to this research. Dr. Bressollette declares he has no conflict of interest related to this research. Dr. Lorillon reports having received personal fees from Astra Zeneca and Bayer, and non-financial support from Pfizer, Novartis, Leo Pharma, Roche and Actelion. Dr. Girard reports having received personal fees and non-financial support from Bayer and Leo Pharma. Dr. Lacut reports having received personal fees from Bayer-Health Care, Bristol-Myers Squibb and Boehringer Ingelheim. Ms. Guégan declares she has no conflict of interest related to this research. Ms. Le Hir declares she has no conflict of interest related to this research. Dr. Bosson declares he has no conflict of interest related to this research. Dr. Laporte reports having received research grant support from Bayer and Sanofi, and fees for board memberships or consultancy from Bayer, Boehringer Ingelheim, Leo Pharma and Sanofi. Dr. Mismetti reports having received research grants from Bayer, fees for board memberships from Bayer, Bristol-Myers Squibb/Pfizer and Daiichi Sankyo, for lectures from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo and Sanofi, and for development of educational presentations from Bayer and Bristol-Myers Squibb/Pfizer. Dr. Bertolletti declares he has no conflict of interest related to this research. Dr. Sanchez reports having received research grant support from Bayer, Daiichi Sankyo and Portola Pharmaceuticals, and fees or non-financial support for consultancy activities from Actelion, GlaxoSmithKline, Boehringer Ingelheim and Chiesi. Dr. Meyer reports having received research grant support from Bayer, Boehringer Ingelheim, Leo Pharma and Sanofi, having been an uncompensated board member and a consultant for Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Leo Pharma and Pfizer, and having received travel support from Bayer, Boehringer Ingelheim, Daiichi Sankyo, Leo Pharma and Sanofi. Dr Leroyer reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer and Astra Zeneca and having received travel support from Bayer, Daiichi Sankyo, Leo Pharma, Intermune and Actelion. Dr Mottier declares he has no conflict of interest related to this research. No other potential conflict of interest relevant to this article was reported.

Contributions: Author contributions: Dr Couturaud had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: F. Couturaud, G. Pernod, P. Mismetti, L. Bertolletti, O. Sanchez, G. Meyer, C. Leroyer, D. Mottier. Acquisition of data: M. Guégan, A. Le Hir. Statistical analysis: S. Laporte, E. Presles. Analysis and interpretation of data: All. Drafting of the manuscript: F. Couturaud, G. Pernod, C. Tromeur, G. Meyer, P. Mismetti, L. Bertolletti, O. Sanchez, S. Laporte, P. Girard, E. Presles, C. Leroyer. Critical revision of the manuscript for important intellectual content: All. Final approval of the manuscript: All. Obtaining funding: F. Couturaud. Administrative, technical, or material support: F. Couturaud, K. Lacut, C. Bal Dit Sollier, M. Guégan, J.L. Bosson, G. Pernod, G. Meyer, D. Mottier, C. Leroyer. Study supervision: F. Couturaud.